earnings
NR
NASDAQ · NRXP
NRx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$2.87
Down-$0.13 (-4.17%)
Updated Sep 29, 2026, 9:19 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.94M
- P/E ratio
- -1.28
- Dividend yield
- 0.00%
- 52-week range
- $1.62 – $5.06
- Volume
- 735.91K
- Avg. volume
- 441.62K
Price performance · NRXP
NRXP price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 28, 2026
NRXP closed at $2.87 after 20 trading sessions, down 17.53% for the selected period.
- Last close
- $2.87
- Period change
- -17.53%
- Period low
- $2.87
- Period high
- $3.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 28, 2026 | $2.95 | $3.01 | $2.87 | $2.87 | 735.91K |
| Sep 25, 2026 | $3.07 | $3.09 | $2.92 | $2.995 | 793.38K |
| Sep 24, 2026 | $3.15 | $3.15 | $3.025 | $3.03 | 681.05K |
| Sep 23, 2026 | $3.29 | $3.35 | $3.12 | $3.16 | 552.5K |
| Sep 22, 2026 | $3.30 | $3.33 | $3.21 | $3.32 | 495.04K |
| Sep 21, 2026 | $3.37 | $3.39 | $3.29 | $3.29 | 380.01K |
| Sep 18, 2026 | $3.38 | $3.42 | $3.31 | $3.32 | 947.27K |
| Sep 17, 2026 | $3.38 | $3.52 | $3.36 | $3.39 | 789.02K |
| Sep 16, 2026 | $3.39 | $3.45 | $3.32 | $3.35 | 716.04K |
| Sep 15, 2026 | $3.46 | $3.47 | $3.16 | $3.40 | 1.26M |
| Sep 14, 2026 | $3.37 | $3.605 | $3.35 | $3.49 | 1.21M |
| Sep 11, 2026 | $3.44 | $3.44 | $3.37 | $3.40 | 356.23K |
| Sep 10, 2026 | $3.36 | $3.45 | $3.32 | $3.40 | 480.12K |
| Sep 9, 2026 | $3.48 | $3.52 | $3.34 | $3.37 | 520.71K |
| Sep 8, 2026 | $3.50 | $3.54 | $3.42 | $3.47 | 705.97K |
| Sep 4, 2026 | $3.43 | $3.50 | $3.39 | $3.49 | 487.72K |
| Sep 3, 2026 | $3.48 | $3.50 | $3.425 | $3.43 | 237.36K |
| Sep 2, 2026 | $3.46 | $3.50 | $3.38 | $3.46 | 418.34K |
| Sep 1, 2026 | $3.45 | $3.51 | $3.42 | $3.44 | 392.76K |
| Aug 31, 2026 | $3.52 | $3.545 | $3.43 | $3.48 | 427.01K |
Latest NRXP news
The latest Smart Investors Daily articles mentioning NRXP.
Stock researchResearch & News · News
Loading stock research…